Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab A/S    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
08/06/2020 08/07/2020 08/10/2020 08/11/2020 08/12/2020 Date
2270(c) 2299(c) 2280(c) 2319(c) 2271 Last
173 741 118 652 125 909 166 110 66 512 Volume
+0.35% +1.28% -0.83% +1.71% -2.07% Change
More quotes
Financials
Sales 2020 9 537 M 1 503 M 1 503 M
Net income 2020 4 632 M 730 M 730 M
Net cash position 2020 13 598 M 2 144 M 2 144 M
P/E ratio 2020 32,1x
Yield 2020 -
Sales 2021 7 788 M 1 228 M 1 228 M
Net income 2021 2 681 M 423 M 423 M
Net cash position 2021 16 165 M 2 548 M 2 548 M
P/E ratio 2021 55,0x
Yield 2021 -
Capitalization 152 B 23 954 M 23 889 M
EV / Sales 2020 14,5x
EV / Sales 2021 17,4x
Nbr of Employees 579
Free-Float 95,1%
More Financials
Company
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (58.8%); - income from research and development (34.8%); - other (6.4%): primarily income from partnership agreement. At the end of 2019, the group had a portfolio of 18 products in... 
Sector
Biotechnology & Medical Research
Calendar
08/12 | 11:00amEarnings Release
More about the company
Surperformance© ratings of Genmab A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on GENMAB A/S
08/07GENMAB A/S : half-yearly earnings release
08/04Nasdaq-Owned Danish Market Is Thriving -- WSJ
DJ
08/03GENMAB A/S : Announces European Myeloma Network and Janssen Achieve Positive Top..
AQ
08/03Nasdaq Indexes Lead Way on Both Sides of Atlantic
DJ
07/31GENMAB A/S : Announces European Myeloma Network and Janssen Achieve Positive Top..
AQ
07/24GLAXOSMITHKLINE : GSK's blood cancer drug wins European panel thumbs-up
RE
07/24GENMAB A/S : GSK's blood cancer drug wins European panel thumbs-up
RE
07/21GENMAB A/S : - Major Shareholder Announcement
AQ
07/20Major Shareholder Announcement
GL
07/17JOHNSON & JOHNSON : Genmab Announces Net Sales of DARZALEX for the Second Quarte..
AQ
07/16Genmab Announces Net Sales of DARZALEX® for the Second Quarter of 2020
GL
07/16GENMAB A/S : 2nd quarter results
CO
07/14GLAXOSMITHKLINE : FDA panel votes in favor of approving GSK's multiple myeloma d..
RE
07/10GLAXOSMITHKLINE : FDA unclear if benefits of GSK multiple myeloma drug outweigh ..
RE
07/08Genmab A/S - Major Shareholder Announcement
AQ
More news
News in other languages on GENMAB A/S
04:20aAVIS D'ANALYSTES DU JOUR : Air Liquide, BMW, Ferrari, Genmab, HelloFresh, Home24..
02:00aEN DIRECT DES MARCHES : Vivendi, Claranova, Just Eat, Tesla, Moderna, Airbnb,..
08/07GENMAB A/S : half-yearly earnings release
08/07GENMAB A/S : Veröffentlichung des Halbjahresergebnisses
08/07GENMAB A/S : publication des résultats semestriels
More news
Stock Trading Strategies
GENMAB A/S - 06/15
The underlying trend is to the upside
BUY
More Stock Trading Analysis
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 2 111,19 DKK
Last Close Price 2 319,00 DKK
Spread / Highest target 11,3%
Spread / Average Target -8,96%
Spread / Lowest Target -52,0%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Deirdre P. Connelly Chairman
Anthony Mancini Chief Operating Officer & Executive Vice President
Anthony Pagano Chief Financial Officer & Executive Vice President
Michael K. Bauer SVP, Head-Operations, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB A/S56.53%23 954
GILEAD SCIENCES, INC.4.80%85 893
VERTEX PHARMACEUTICALS19.60%69 995
REGENERON PHARMACEUTICALS59.49%64 005
WUXI APPTEC CO., LTD.72.11%38 467
BEIGENE, LTD.26.36%18 947